Biosimilars Forum Welcomes PBM Transparency Act
US Proposals Would See Spread Pricing Outlawed And Rebates Disclosed
Executive Summary
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
You may also be interested in...
AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact
The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.
Industry Hails Access Implications As FTC Promises PBM Probe
The US FTC’s announcement of an inquiry into PBMs will be music to the ears of the country’s generics and biosimilars industry, which has long called for action on abusive practices that undermine access.
AAM Calls Out Threat Of Consolidation Among Purchasers
Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.